Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for breast cancer screening
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer screening or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on breast cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
The Association of Health Literacy with BreastCancer Knowledge, Perception and Screening Behavior The incidence of breastcancer among Iranian women is increasing, and 70% of patients are diagnosed at advanced stages. The current study aimed at evaluating the association of health literacy (HL) with breastcancer knowledge, perception, and screening behavior in women.The current cross- sectional, descriptive study was conducted on 250 women who referred to health centers in Zahedan, Iran. Data (...) ), and with perceived susceptibility.Interventions to enhance breastcancer knowledge and screening should notice the HL of women.
Automated and Clinical Breast Imaging Reporting and Data System Density Measures Predict Risk of Screen-Detected and Interval Cancers. In 30 states, women who have had screening mammography are informed of their breast density on the basis of Breast Imaging Reporting and Data System (BI-RADS) density categories estimated subjectively by radiologists. Variation in these clinical categories across and within radiologists has led to discussion about whether automated BI-RADS density should (...) be reported instead.To determine whether breastcancer risk and detection are similar for automated and clinical BI-RADS density measures.Case-control.San Francisco Mammography Registry and Mayo Clinic.1609 women with screen-detected cancer, 351 women with interval invasive cancer, and 4409 matched control participants.Automated and clinical BI-RADS density assessed on digital mammography at 2 time points from September 2006 to October 2014, interval and screen-detected breastcancer risk, and mammography
A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breastcancer metastasis Tumor cells disseminate early in tumor development making metastasis-prevention strategies difficult. Identifying proteins that promote the outgrowth of disseminated tumor cells may provide opportunities for novel therapeutic strategies. Despite multiple studies demonstrating that the mesenchymal-to-epithelial transition (MET) is critical for metastatic colonization, key regulators (...) that initiate this transition remain unknown. We serially passaged lung metastases from a primary triple negative breastcancer xenograft to the mammary fat pads of recipient mice to enrich for gene expression changes that drive metastasis. An unbiased transcriptomic signature of potential metastatic drivers was generated, and a high throughput gain-of-function screen was performed in vivo to validate candidates. Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) was identified
The overestimation and the inappropriate promotion of the benefits of mammographic screening in breastcancer research and interventions in the Gaza Strip. There has been extensive debate about whether mammographic screening has done more good than harm. Recent reviews showed that women who undergo mammographic screening are more likely to have a tumour that was an overdiagnosis and therefore would not cause them problems. In the Gaza Strip, a strong forum of people advocate an increase (...) women have low survival rates because of the poor availability of mammography. Only three study groups mentioned harmful effects of mammographic screening. All educational materials had clear information on the benefits of mammographic screening but minimal information on its harms.Research in the Gaza Strip overestimated the reduction in breastcancer mortality that can be attributable to mammographic screening, and this would encourage women to undergo screening without knowing that it could harm
Association of Screening and Treatment With BreastCancer Mortality by Molecular Subtype in US Women, 2000-2012. Given recent advances in screening mammography and adjuvant therapy (treatment), quantifying their separate and combined effects on US breastcancer mortality reductions by molecular subtype could guide future decisions to reduce disease burden.To evaluate the contributions associated with screening and treatment to breastcancer mortality reductions by molecular subtype based (...) , overall, and ER/ERBB2-specific breastcancer mortality rates from 2000 to 2012 for women aged 30 to 79 years relative to the estimated mortality rate in the absence of screening and treatment (baseline rate); mortality reductions were apportioned to screening and treatment.In 2000, the estimated reduction in overall breastcancer mortality rate was 37% (model range, 27%-42%) relative to the estimated baseline rate in 2000 of 64 deaths (model range, 56-73) per 100 000 women: 44% (model range, 35%-60
with early invasive breastcancer. Intra-operative analysis is not a requirement.BEST PRACTISE GUIDELINES foR SURGE oNS IN BREASTCANCERSCREENING 8 5. TREATMENT of SCREEN-DETECTED BREASTCANCER Surgeons involved in the treatment of screen-detected breastcancer must be aware of all treatment options available. Women with screen-detected breastcancer generally present with earlier stage disease and with a higher proportion of DCIS than in symptomatic practice. However, once diagnosed the treatment (...) screening pathway begins with the identification of eligible women through batch specification and includes mammography, the assessment of presumptive signs of malignancy, diagnostic and therapeutic surgery and pathology. The screening programme ends with the diagnosis of cancer or the completion of the screening programme at 70 years of age. Breastscreening QA is described in the Programme Specific Operating Model for BreastScreening QA and includes the surgeon’s role in the diagnosis and management
. An alternative approach, for many of these lesions, is thorough sampling/excision by vacuum- assisted biopsy techniques to exclude the presence of co-existing carcinoma. This would potentially reduce the benign open biopsy rate whilst maintaining accuracy of cancer diag- nosis. A group from the Radiology, Surgery, and Pathology NHS BreastScreening Programme Co-ordinating Committees and an additional co-opted expert were charged with review and development of guidelines for the clinical management of B3 (...) diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. Int J Canc 2011 Sep 15;129(6):1417e24. 6. Yu YH, Liang C, Yuan XZ. Diagnostic value of vacuum-assisted breast biopsy for breastcarcinoma: a meta-analysis and systematic review. Breast Canc Res Treat 2010 Apr;120(2):469e79. 7. Canas-MarquesR,SchnittSJ.E-cadherinimmunohistochemistryinbreast pathology: uses and pitfalls. Histopathology 2016 Jan;68(1):57e69. https://doi.org/10.1111/his.12869. 8
BreastCancerScreening Behaviors of First Degree Relatives of Women Receiving BreastCancer Treatment and the Affecting Factors First-degree relatives of women with breastcancer are under higher risk when compared with the general population. The aim of this study is to evaluate breastcancerscreening behaviors of women who are first-degree relatives of women with breastcancer and factors affecting these behaviors.This descriptive study included 240 patient relatives, who agreed (...) to participate in the study through contact with first-degree relatives of 133 patients who were receiving breastcancer treatment at the Oncology and Chemotherapy unit of an university hospital in Turkey. Data were collected using the "Descriptive Characteristics Form," which consisted of socio-demographic characteristics, health history, breastcancer risk level and health beliefs as well as the "BreastCancerScreening Behavior Evaluation Form".Out of the subjects, 17% reported doing breast self
â€œThanks for Letting Us All Share Your Mammogram Experience Virtuallyâ€: Developing a Web-Based Hub for BreastCancerScreening The decision around whether to attend breastcancerscreening can often involve making sense of confusing and contradictory information on its risks and benefits. The Word of Mouth Mammogram e-Network (WoMMeN) project was established to create a Web-based resource to support decision making regarding breastcancerscreening. This paper presents data from our user (...) to explore the advantages and limitations of this approach. The second objective was to analyze what women want from a Web-based resource for breastcancer screening.We recruited a user design group on Facebook and conducted a survey within the group, asking questions about design considerations for a Web-based breastcancerscreening hub. Although the membership of the Facebook group varied over time, there were 71 members in the Facebook group at the end point of analysis. We next conducted a framework
risk for a specific tumor type, generating new data that can inform best practices rather than to continue the rancorous debate. It is time to move from debate to wisdom by asking new questions and generating new knowledge. The WISDOM Study (Women Informed to Screen Depending On Measures of risk) is a pragmatic, adaptive, randomized clinical trial comparing a comprehensive risk-based, or personalized approach to traditional annual breastcancerscreening. The multicenter trial will enroll 100,000 (...) The WISDOM Study: breaking the deadlock in the breastcancerscreening debate There are few medical issues that have generated as much controversy as screening for breastcancer. In science, controversy often stimulates innovation; however, the intensely divisive debate over mammographic screening has had the opposite effect and has stifled progress. The same two questions-whether it is better to screen annually or bi-annually, and whether women are best served by beginning screening at 40
Cost-Effectiveness of BreastCancerScreening in Turkey, a Developing Country: Results from BahÃ§eÅŸehir Mammography Screening Project We used the results from the first three screening rounds of Bahcesehir Mammography Screening Project (BMSP), a 10-year (2009-2019) and the first organized population-based screening program implemented in a county of Istanbul, Turkey, to assess the potential cost-effectiveness of a population-based mammography screening program in Turkey.Two screening (...) strategies were compared: BMSP (includes three biennial screens for women between 40-69) and Turkish National BreastCancer Registry Program (TNBCRP) which includes no organized population-based screening. Costs were estimated using direct data from the BMSP project and the reimbursement rates of Turkish Social Security Administration. The life-years saved by BMSP were estimated using the stage distribution observed with BMSP and TNBCRP.A total of 67 women (out of 7234 screened women) were diagnosed
Evaluation on the Practice and Behaviour of Women Applied for Gynecology Outpatient Clinics About Screening Methods for Early Diagnosis of BreastCancerBreast self-examination (BSE), clinical breast exam (CBE), mammography and ultrasound imaging (UI) are screening methods used for early diagnosis of breastcancer (BC). The purpose of this study is to put forth the utilization frequency of these screening methods among women presenting to the gynecology outpatient clinics and the relation (...) mammography and CBE are at less-than-ideal levels. In this context, it is apparent that breastcancerscreening methods are needed to be introduced and guidance about their application frequency should be provided for women in gynecology outpatient clinics.
BreastCancerScreening in Women at Above Average Risk Oregon Health Authority : Health Evidence Review Commission : Health Evidence Review Commission : State of Oregon menu Toggle Main Menu Main Navigation close search Search search Submit You are here: Health Evidence Review Commission menu Site Navigation Health Evidence Review Commission Full Width Column 1 Health Evidence: Our Role The Health Evidence Review Commission reviews medical evidence in order to prioritize health spending
in radiological surveillance (retrospective mammographic review) of interval breastcancers, this form of surveillance consistently reveals that the majority of interval cancers represent either true interval or occult cancers that were not visible on the index mammographic screen; approximately 20-25% of interval breastcancers are classified as having been missed (false-negatives). The biological characteristics of interval breastcancers show that they have relatively worse tumour prognostic (...) The epidemiology, radiology and biological characteristics of interval breastcancers in population mammography screening An interval breastcancer is a cancer that emerges following a negative mammographic screen. This overview describes the epidemiology, and the radiological and biological characteristics of interval breastcancers in population mammography screening. Notwithstanding possible differences in ascertainment of interval breastcancers, there was broad variability in reported
[Invitation and decision guide for breastcancerscreening] Einladungsschreiben und entscheidungshilfe zum mammographie-screening: abschlussbericht; auftrag P14-0 [Invitation and decision guide for breastcancerscreening] Einladungsschreiben und entscheidungshilfe zum mammographie-screening: abschlussbericht; auftrag P14-0 [Invitation and decision guide for breastcancerscreening] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Einladungsschreiben und entscheidungshilfe zum mammographie-screening: abschlussbericht; auftrag P14-0. [Invitation and decision guide for breastcancerscreening] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG
Magnetic Resonance Imaging as an Adjunct to Mammography for BreastCancerScreening in Women at Less Than High Risk for BreastCancer Magnetic Resonance Imaging as an Adjunct to Mammography for BreastCancerScreening in Women at Less Than High Risk for BreastCancer - Health Quality Ontario (HQO) Let's make our health system healthier Open Menu Quick Links Search Search A A A Evidence to Improve Care Share: Magnetic Resonance Imaging as an Adjunct to Mammography for BreastCancerScreening (...) in Women at Less Than High Risk for BreastCancer Ontario Health Technology Advisory Committee Recommendation The Ontario Health Technology Advisory Committee recommends against publicly funding screeningbreast magnetic resonance imaging (MRI) as an adjunct to screening mammography for women who are at less than high risk for breastcancer and who have no personal history of breastcancerBreastcancer is the most common cancer among Canadian women. The most common form of screening for breastcancer
. Importantly, accurate and reliable risk estimation and strati?cation for malignancy risk is highly problematicformostofthegenesidenti?edinthesepanels. The following genes might have moderate- to high- penetrance germline mutations for breast or ovarian cancer: p53, PTEN, CDH1, PALB2, CHEK2, ATM, RAD51C, STK11, RAD51D, BRIP1, MLH1, MSH2, MSH6 and PMS2. Prevention and screening strategies for these mutations are summarised in Table 1—due to limited research in individuals harbouring these mutations (...) Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer Syndromes PreventionandscreeninginBRCAmutationcarriersand otherbreast/ovarianhereditarycancersyndromes: ESMOClinicalPracticeGuidelinesforcancerprevention andscreening † S.Paluch-Shimon 1 ,F.Cardoso 2 ,C.Sessa 3 ,J.Balmana 4 ,M.J.Cardoso 2 ,F.Gilbert 5 &E.Senkus 6 , onbehalfoftheESMOGuidelinesCommittee * 1 DivisionofOncologyandtheDrPinchasBorensteinTalpiotMedicalLeadershipProgram,ShebaMedicalCenter
. The majority of women (94%) knew about breastcancer, whereas 27.5% knew someone who had had breastcancer, the majority of whom (64.5%) had died of the disease. Of the 36% of women who had breastscreening recommended to them, only 19.7% had an actual CBE. Of these, only 6% had it in the last year. The majority of women (65.4%) were willing to have regular CBEs and did not care about the sex of the examiner in most instances. Lack of perceived need was the reason cited by women unwilling (...) Developing a BreastCancerScreening Program in Nigeria: Evaluating Current Practices, Perceptions, and Possible Barriers In low- and middle-income countries like Nigeria, women present with advanced breastcancer at an earlier age. Given the limited resources, development of screening programs that parallel resource capabilities of low- and middle-income countries is imperative. The objective of this study was to evaluate the perceptions, practices, and barriers regarding clinical breast
and nonscreening areas.Screening was not associated with lower incidence of advanced tumors. The incidence of nonadvanced tumors increased in the screening versus prescreening periods (incidence rate ratio, 1.49 [95% CI, 1.43 to 1.54]). The first estimation approach found that 271 invasive breastcancertumors and 179 ductal carcinoma in situ (DCIS) lesions were overdiagnosed in 2010 (overdiagnosis rate of 24.4% [including DCIS] and 14.7% [excluding DCIS]). The second approach, which accounted for regional (...) BreastCancerScreening in Denmark: A Cohort Study of Tumor Size and Overdiagnosis. Effective breastcancerscreening should detect early-stage cancer and prevent advanced disease.To assess the association between screening and the size of detected tumors and to estimate overdiagnosis (detection of tumors that would not become clinically relevant).Cohort study.Denmark from 1980 to 2010.Women aged 35 to 84 years.Screening programs offering biennial mammography for women aged 50 to 69 years
improve patient management and health outcomes? Are there any safety issues associated with the use of DBT? Have definitive patient selection criteria been established for DBT for screening or diagnosis of breastcancer? Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH BreastNeoplasms; Humans; Mammography; Tomography, X-Ray Language Published English Country of organisation United States English summary An English language summary (...) Digital breast tomosynthesis for breastcancer diagnosis and screening Digital breast tomosynthesis for breastcancer diagnosis and screening Digital breast tomosynthesis for breastcancer diagnosis and screening HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Digital breast tomosynthesis for breastcancer diagnosis and screening. Lansdale